UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
(Amendment No. 3)
GENENTECH, INC.
(Name of Subject Company)
GENENTECH, INC.
(Name of Person Filing Statement)
Common Stock, par value $0.02 per share
(Title of Class of Securities)
368710406
(CUSIP Number of Class of Securities)
Sean A. Johnston
Genentech, Inc.
1 DNA Way
South San Francisco, California 94080-4990
(650) 225-1000
(Name, address and telephone number of person authorized to receive
notices and communications on behalf of the persons filing statement)
With copies to:
| Charles M. Nathan | Larry W. Sonsini | |
| John M. Newell | Martin W. Korman | |
| Latham & Watkins LLP | Wilson Sonsini Goodrich & Rosati | |
| 885 Third Avenue | Professional Corporation | |
| New York, New York 10022-4834 | 650 Page Mill Road | |
| (212) 906-1200 | Palo Alto, California 94304 | |
| (650) 493-9300 |
| ¨ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Amendment No. 3 to the Solicitation/Recommendation Statement on Schedule 14D-9 (the “Schedule 14D-9”) amends and supplements the Schedule 14D-9, originally filed by Genentech, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “SEC”) on February 23, 2009, as amended, relating to the tender offer commenced by Roche Investments USA Inc. (“Roche Investments”) pursuant to which Roche Investments has offered to purchase all the outstanding Common Stock, par value $0.02 per share (the “Shares”) of the Company not owned by Roche Holding Ltd (“Roche Holding” and together with its affiliates (excluding the Company and its subsidiaries) and Roche Investments, “Roche”) at $86.50 per Share, upon the terms and conditions set forth in the Offer to Purchase dated February 9, 2009 and the related Letter of Transmittal (which together with the Offer to Purchase and any amendments or supplements thereto, collectively, constitute the “Offer”) contained in the Schedule TO filed by Roche Investments with the SEC on February 9, 2009. Capitalized terms used but not defined herein have the meaning ascribed to them in the Schedule 14D-9.
| Item 9. | Exhibits. |
Item 9 is hereby amended and supplemented by adding the following thereto:
| (a)(8) | Transcript of Investor Presentation held on March 2, 2009 |
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
| GENENTECH, INC. | ||||
| By: | /s/ Stephen Juelsgaard | |||
| Name: | Stephen Juelsgaard | |||
| Title: | Executive Vice President, Secretary and Chief Compliance Officer | |||
| Dated: March 3, 2009 | ||||